GSK

GSK nabs speedy review for one of its top prospects
GSK nabs speedy review for one of its top prospects
Fierce Biotech
GSK
FDA
priority review
BCMA
belantamab mafodotin
relapsed or refractory multiple myeloma
Flag link:
GlaxoSmithKline halts Excedrin production over manufacturing stumble
GlaxoSmithKline halts Excedrin production over manufacturing stumble
Fierce Pharma
GSK
consumer health
Pfizer
Excederin
drug manufacturing
Flag link:
Who are the 10 Most Innovative Biopharma Companies?
Who are the 10 Most Innovative Biopharma Companies?
BioSpace
innovation
Regeneron
Verily
Illumina
Biogen
Bayer
Bluebird Bio
Novartis
GSK
Genentech
Amgen
Flag link:
JPM: Glaxo sees enormous Shingrix potential, but a supply gap still stands in the way
JPM: Glaxo sees enormous Shingrix potential, but a supply gap still stands in the way
Fierce Pharma
GSK
vaccines
Shingrix
shingles
drug shortages
JPMHC 2020
Flag link:
GSK, Pfizer contradict on the future of consumer health JV — report
GSK, Pfizer contradict on the future of consumer health JV — report
Endpoints
GSK
Pfizer
consumer health
JPMHC 2020
Flag link:
GSK’s CEO Walmsley aiming for six new approvals in 2020
GSK’s CEO Walmsley aiming for six new approvals in 2020
Pharmaforum
GSK
Pharma CEOs
Emma Walmsley
JPMHC 2020
Zejula
Trelegy
daprodustat
belantamab mafodotin
Flag link:
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
Flag link:
GSK's plan to take over the HIV drug market hasn't worked out
GSK's plan to take over the HIV drug market hasn't worked out
BioPharma Dive
GSK
FDA
HIV
Dovato
Biktarvy
ViiV Healthcare
Gilead Sciences
Flag link:
GlaxoSmithKline consolidates Pfizer consumer brands under Publicis Media specialty unit
GlaxoSmithKline consolidates Pfizer consumer brands under Publicis Media specialty unit
Fierce Pharma
GSK
consumer health
Publicis Media
Flag link:
GSK closes sale of two vaccine brands to Bavarian Nordic
GSK closes sale of two vaccine brands to Bavarian Nordic
Pharmaceutical Business Review
GSK
vaccines
Bavarian Nordic
Rabipur
Encepur
travel vaccines
Flag link:
FDA slams GSK's monthly HIV injectable with CRL, citing manufacturing issues
FDA slams GSK's monthly HIV injectable with CRL, citing manufacturing issues
Endpoints
FDA
complete response letter
GSK
HIV
cabotegravir
rilpivirine
Flag link:
Is there a future for pharma in neuro?
Is there a future for pharma in neuro?
Fierce Biotech
Neuroscience
R&D
Eli Lilly
Amgen
GSK
Novartis
Flag link:
GSK finds synergies with global marketing strategy
GSK finds synergies with global marketing strategy
Pharmaforum
GSK
Flag link:
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Fierce Pharma
oncology
Rare Diseases
AstraZeneca
GSK
Alexion
Takeda
Soliris
Flag link:
Roche's Ocrevus, GSK's Dovato ads top November TV spending charts—behind Humira, of course
Roche's Ocrevus, GSK's Dovato ads top November TV spending charts—behind Humira, of course
Fierce Pharma
drug ads
television ads
Roche
Ocrevus
GSK
Dovato
AbbVie
Humira
Flag link:
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
Biopharma Dive
AstraZeneca
lupus
anifrolumab
GSK
Benlysta
Flag link:
GlaxoSmithKline's Benlysta eyes lupus sales boost after kidney trial win
GlaxoSmithKline's Benlysta eyes lupus sales boost after kidney trial win
Fierce Pharma
GSK
Benlysta
lupus
Flag link:
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Pharmaforum
Novartis
Europe
GSK
Sanofi
AstraZeneca
Roche
Flag link:
GSK poised to leap back into the oncology market with more positive belantamab mafodotin results — but BCMA rivals are swarming in behind
GSK poised to leap back into the oncology market with more positive belantamab mafodotin results — but BCMA rivals are swarming in behind
Endpoints
GSK
Multiple Myeloma
belantamab mafodotin
clinical trials
Flag link:
GSK's ViiV seeks marketing license for baby-friendly HIV pill
GSK's ViiV seeks marketing license for baby-friendly HIV pill
Reuters
GSK
HIV
Dolutegravir
pediatric
Flag link:

Pages